Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 24Breast Neoplasms 22Head and Neck Neoplasms 14Adenocarcinoma of Lung 11Neoplasms 7Esophageal Neoplasms 7Brain Neoplasms 7Prostatic Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Glioblastoma 5Adenocarcinoma Of Esophagus 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Ovarian Neoplasms 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Skin Neoplasms 2Neoplasms, Squamous Cell 2Mesothelioma, Malignant 2Lymphoid Interstitial Pneumonia 2Laryngeal Diseases 2

Interventions

Capecitabine 4Temozolomide 3Octreotide 3Streptozocin 2Fluorouracil 2Everolimus 2vatalanib 1romidepsin 1regorafenib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Omeprazole 1Leucovorin 1Irinotecan 1Gefitinib 1Doxorubicin 1Cisplatin 1Bortezomib 1Biological Therapy 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrinoma × Gefitinib × Clear all
NCT00075439 2013-06-04

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
90 enrolled
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡